Stocktoria
Divi's Laboratories Limited DIVISLAB.NS
Divi's Laboratories Limited (DIVISLAB.NS) earns a Piotroski F-score of 5/9 (mixed financial health). It pays a dividend yielding 0.46% (safety: safe). FY2026 revenue was ₹105.6B at a 24.3% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 46 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
FAQ
Is DIVISLAB.NS financially healthy?
Divi's Laboratories Limited's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does DIVISLAB.NS pay a dividend, and is it safe?
Yes. Divi's Laboratories Limited pays a dividend yielding about 0.46% with a 31.0% payout ratio, rated “safe” for safety.
How profitable is DIVISLAB.NS?
In FY2026, Divi's Laboratories Limited had a net margin of 24.3% and a return on equity of 15.3%.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.